Semaglutide vs Tirzepatide: GLP-1 vs Dual GIP/GLP-1 Peptides Compared

The GLP-1 receptor agonist class has transformed obesity medicine. Semaglutide (Ozempic, Wegovy) dominated the conversation from 2021–2023. Tirzepatide (Mounjaro, Zepbound) arrived shortly after and in head-to-head data, it wins on weight loss outcomes—often significantly. But the comparison involves more than efficacy; cost, side effects, availability, and off-label access matter enormously for most patients.

What semaglutide is

Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a natural incretin hormone produced in the gut after eating. It signals the pancreas to release insulin, suppresses glucagon, slows gastric emptying, and—critically—acts on the hypothalamus to reduce appetite.

Semaglutide is a synthetic analog of GLP-1 with a 94% structural homology to native GLP-1 but with modifications that extend its half-life to approximately seven days—allowing once-weekly dosing.

Approved indications:

• Ozempic (0.5–2mg/week): Type 2 diabetes management; cardiovascular risk reduction in T2D
• Wegovy (2.4mg/week): Obesity treatment in adults with BMI ≥30 or ≥27 with weight-related comorbidity
• Rybelsus: Oral semaglutide for T2D (lower systemic exposure than injectable)

Weight loss data: In the STEP 1 trial, semaglutide 2.4mg/week produced 14.9% average body weight reduction over 68 weeks. In STEP 2 (T2D population), 9.6%.

What tirzepatide is

Tirzepatide is a dual agonist—it activates both GLP-1 receptors AND GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is a second incretin hormone that works through a different but complementary pathway: it potentiates insulin secretion, promotes fat storage in adipocytes (which paradoxically may enhance the metabolic response when combined with GLP-1 antagonism), and appears to modulate energy homeostasis centrally.

The dual mechanism is why tirzepatide outperforms semaglutide. By hitting two incretin pathways simultaneously, it produces greater appetite suppression, greater insulin sensitization, and greater effects on adipose tissue metabolism.

Approved indications:

• Mounjaro (2.5–15mg/week): Type 2 diabetes management
• Zepbound (2.5–15mg/week): Obesity treatment

Weight loss data:

The SURMOUNT-1 trial produced headline numbers that changed the field:

• Tirzepatide 5mg: −15.0% body weight
• Tirzepatide 10mg: −19.5% body weight
• Tirzepatide 15mg: −20.9% body weight (placebo: −3.1%)

These are bariatric surgery-level results from a weekly injection.

Head-to-head: SURPASS-2 and real-world data

The SURPASS-2 trial directly compared tirzepatide to semaglutide 1mg (the standard T2D dose, not the higher obesity dose) over 40 weeks:

• Tirzepatide 5mg: −1.86% HbA1c vs. semaglutide −1.86% (similar at low dose)
• Tirzepatide 10mg: −2.09% HbA1c; weight −8.8kg vs. semaglutide −5.7kg
• Tirzepatide 15mg: −2.37% HbA1c; weight −11.2kg vs. semaglutide −5.7kg

Note that SURPASS-2 used semaglutide 1mg, not 2.4mg (Wegovy dose). Direct comparison against high-dose semaglutide was not available in a single trial until real-world studies began accumulating.

A 2023 real-world study in JAMA Internal Medicine comparing patients initiated on tirzepatide vs. semaglutide found tirzepatide users lost 2–3% more body weight at 6 months, consistent with trial data.

The consensus in 2026: Tirzepatide produces meaningfully greater weight loss than semaglutide at maximum doses. For patients whose primary goal is maximum weight reduction, tirzepatide is the stronger tool.

Side effect comparison

Both drugs share a class-effect side effect profile due to GLP-1 receptor activation:

Shared side effects:

• Nausea (most common, especially on dose escalation): 44% with tirzepatide, 40% with semaglutide
• Vomiting: 25% vs. 24%
• Diarrhea: 23% vs. 20%
• Constipation: 11% vs. 11%
• Decreased appetite (desired and adverse)

These GI symptoms are largely dose-dependent and improve after the first 4–8 weeks on a stable dose. Slow dose escalation is the primary mitigation strategy.

Differences:

• Injection site reactions: Similar rates
• Pancreatitis risk: Class effect, rare for both; similar incidence
• Thyroid C-cell tumors: Both carry a black box warning based on rodent carcinogenicity data; human relevance is unclear and no increased thyroid cancer signal has emerged in human trials
• Tirzepatide-specific: Some evidence of slightly more tolerability at high doses compared to semaglutide (possibly due to GIP receptor modulation buffering some GLP-1-mediated nausea)
• Muscle loss: Both drugs produce some lean mass loss with weight reduction—a concern that should be addressed with resistance training and adequate protein intake

Cardiovascular data

Semaglutide: The SELECT trial (2023) demonstrated semaglutide 2.4mg reduced major adverse cardiovascular events (MACE) by 20% in obese adults without diabetes—the first obesity drug with proven cardiovascular benefit. This is a major finding that goes beyond weight loss.

Tirzepatide: The SURPASS-CVOT trial (SURMOUNT-MMO) is ongoing. Preliminary data and the SURPASS-3/4/5 series show favorable cardiovascular risk factor profiles. Full CVOT data expected by 2026–2027. As of now, tirzepatide does not have semaglutide's level of cardiovascular outcome evidence.

For patients with established cardiovascular disease who need a GLP-1 agonist, semaglutide currently has the stronger cardiovascular evidence base.

Cost comparison in 2026

Brand-name GLP-1 agonists:

| Product | List Price/Month (US) | With Insurance | |---|---|---| | Wegovy (semaglutide 2.4mg) | ~$1,350 | $25–$500 depending on plan | | Ozempic (semaglutide, T2D) | ~$900 | Often covered for T2D | | Zepbound (tirzepatide, obesity) | ~$1,060 | Growing coverage | | Mounjaro (tirzepatide, T2D) | ~$1,000 | Covered for T2D |

Compounded semaglutide and tirzepatide:

Following FDA drug shortage listings, compounding pharmacies have legally produced both semaglutide and tirzepatide. Compounded versions cost $150–$400/month and have made these medications accessible to a far broader population. However, the FDA has moved to end the shortage status designation for semaglutide, meaning compounding availability may diminish. The regulatory landscape is evolving.

Research peptide suppliers:

Both semaglutide and tirzepatide are available from research peptide vendors at significantly lower cost, though outside physician oversight. See GLP-1 peptides guide for a full discussion of the access landscape.

Which to choose

Choose semaglutide (Wegovy/Ozempic) if:

• You have established cardiovascular disease and want proven CV outcome data
• You are sensitive to new mechanisms and want more clinical experience in the literature
• Insurance covers Wegovy but not Zepbound for your indication
• You want a well-established dosing and tolerability protocol

Choose tirzepatide (Zepbound/Mounjaro) if:

• Maximum weight loss is the primary goal
• You have type 2 diabetes and want superior HbA1c reduction
• GI side effects were limiting on semaglutide (tirzepatide may be better tolerated)
• You want the most advanced dual-mechanism approach available

For most patients whose primary goal is weight loss and who don't have prior cardiovascular events, tirzepatide is likely the better choice based on current evidence. For patients with prior MACE, semaglutide's SELECT data makes it the more evidenced option.

See also best peptides for fat loss and peptides for weight loss for context on where GLP-1s fit in the broader peptide landscape.

Frequently Asked Questions

Q: Is tirzepatide really much better than semaglutide for weight loss? Yes, in clinical trials the difference is meaningful. The SURMOUNT-1 showed 20.9% weight loss at max tirzepatide dose vs. 14.9% for semaglutide 2.4mg in STEP 1. That's roughly 6 percentage points, which translates to ~15–20 additional pounds on a typical patient. The difference is clinically significant.

Q: Why does tirzepatide work better than a pure GLP-1? The GIP receptor agonism appears to potentiate GLP-1's effects through complementary CNS pathways. GIP receptors are expressed in the hypothalamus and brainstem in regions involved in energy balance. The combination creates greater appetite suppression and metabolic effects than either mechanism alone.

Q: Can I switch from semaglutide to tirzepatide? Yes. Most clinicians transitioning patients stop semaglutide and restart tirzepatide from a low dose with standard escalation. There is no required washout period given the different receptors involved, but individual prescriber protocols vary.

Q: What about muscle loss on GLP-1 agonists? Both drugs produce some muscle loss as a proportion of total weight lost—typically 25–40% of total weight lost is lean mass when not exercising. Resistance training 2–3x/week and high protein intake (1.2–1.6g/kg body weight) can substantially attenuate muscle loss. Some clinicians add ipamorelin/CJC-1295 to GLP-1 protocols to preserve lean mass.

---

Track your GLP-1 protocol progress and body composition changes. Use Optimize free.